Dendreon price target lowered to $4 from $5 at William Blair William Blair lowered its price target for Dendreon after the company's Q3 Provenge sales missed expectations. The firm expects sales of the drug to remain challenged and keeps an Underperform rating on the stock.
News For DNDN From The Last 14 Days
Check below for free stories on DNDN the last two weeks.
